Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004
Sponsor: Amgen
This PHASE4 trial investigates Giant Cell Tumor of Bone and is currently completed. Amgen leads this study, which shows 23 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Study Description(click to expand)Study 20140114 will continue to follow participants with GCTB who were treated in Study 20062004 and remained on the study at the completion of Study 20062004 for an additional 5 years on long-term safety follow up. Collection of long-term safety information will include adverse events of interest and all treatment-emergent adverse events and serious adverse events
Study 20140114 will continue to follow participants with GCTB who were treated in Study 20062004 and remained on the study at the completion of Study 20062004 for an additional 5 years on long-term safety follow up. Collection of long-term safety information will include adverse events of interest and all treatment-emergent adverse events and serious adverse events
Status Flow
Change History
23 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE4
-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE4
▶ Show 18 earlier versions
-
Nov 2023 — Jun 2024 [monthly]
Completed PHASE4
-
Sep 2023 — Nov 2023 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Jan 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE4
-
Jan 2022 — Jan 2023 [monthly]
Active Not Recruiting PHASE4
-
Oct 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE4
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE4
-
Nov 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE4
-
Jan 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE4
-
Nov 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE4
-
Aug 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE4
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE4
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE4
-
Mar 2018 — May 2018 [monthly]
Recruiting PHASE4
-
Feb 2018 — Mar 2018 [monthly]
Recruiting PHASE4
-
Jan 2018 — Feb 2018 [monthly]
Recruiting PHASE4
-
Dec 2017 — Jan 2018 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Oct 2017 — Dec 2017 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen
For direct contact, visit the study record on ClinicalTrials.gov .